OncoMatch/Clinical Trials/NCT04696029
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Is NCT04696029 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Difluoromethylornithine for medulloblastoma.
Treatment: Difluoromethylornithine — Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: MYC amplification
MYC amplified Group 3
Required: MYCN amplification
MYCN amplified
Required: TP53 mutation
TP53 mutant non-infant (>3 yrs) SHH
Disease stage
Required: Stage IV
Molecular High Risk and Very High Risk definitions include metastatic status; relapsed/refractory cohort included
Demographics
Prior therapy
Cannot have received: investigational drug
Subjects who are currently receiving another investigational drug are excluded from participation.
Cannot have received: anticancer agents
Subjects who are currently receiving other anticancer agents are not eligible.
Lab requirements
Blood counts
anc ≥750/μl, platelets ≥30 (non-transfused x 7 days)
Kidney function
creatinine clearance or radioisotope gfr ≥ 70 ml/min/1.73 m2 or a serum creatinine based on age/gender
Liver function
ast and alt <10x upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arkansas Children's Hospital · Little Rock, Arkansas
- UCSF Benioff Children's Hospital Oakland · Oakland, California
- Rady Children's Hospital · San Diego, California
- Stanford University · Stanford, California
- Connecticut Children's Hospital · Hartford, Connecticut
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04696029 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational drug, anticancer agents disqualifies patients from enrollment.
Does this trial require MYC?
Yes, MYC amplification is a required biomarker for enrollment.
Does this trial require MYCN?
Yes, MYCN amplification is a required biomarker for enrollment.
Does this trial require TP53?
Yes, TP53 mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages